{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:15:57Z","timestamp":1773332157836,"version":"3.50.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T00:00:00Z","timestamp":1703289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>A substantial number of patients with multiple myeloma (MM) who have bone destruction are initially admitted into the orthopedic service at the hospital. However, routine laboratory testing usually fails to identify these patients, thus delaying optimal therapy. Therefore, there is a clear medical need for early diagnosis of MM in these patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Between 2019 and 2021, 42 patients receiving treatment for orthopedic conditions had normal hemoglobin (Hb), total protein (TP), albumin (ALB), creatinine (CREA), and blood calcium (Ca) levels before their surgical procedure(s) but were subsequently pathologically confirmed to have MM, based on their presenting orthopedic symptoms. During the same period, 52 patients with orthopedic conditions were pathologically excluded from the diagnosis of MM and were recruited into our control group. Serum free light chain (sFLC) testing was performed in 94 consecutive patients in the orthopedic service using Siemens N Latex FLC kits. The levels of Hb, TP, ALB, CREA, and Ca were also measured. All 42 patients with MM were divided into group A (n = 25: \u03ba proliferation) and group B (n = 17: \u03bb proliferation) by the pathology department.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were no significant differences in levels of Hb, TP, ALB, CREA, and Ca between group A and group B and the control group. However, the sFLC \u03ba\/\u03bb ratio of group A and B was also significantly different from that of the control group (P &amp;lt; .001). The results of serum immunofixation electrophoresis (IFE) testing demonstrated negative results in 14 cases (58.3%) in group A and 4 cases (25.0%) in group B.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Some patients with orthopedic conditions who do not have typical MM laboratory results, such as those with abnormal Hb, TP, ALB, CREA, and Ca levels before their operation(s), actually have MM. MM should be highly suspected in patients with unexplained bone lesions and with an abnormal sFLC \u03ba\/\u03bb ratio. Further tissue or bone marrow biopsy is needed in these patients even if serum and urine IFE results are negative and light chain ratio is normal.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/labmed\/lmad104","type":"journal-article","created":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T20:25:58Z","timestamp":1703363158000},"page":"454-459","source":"Crossref","is-referenced-by-count":1,"title":["Urine immunofixation electrophoresis and serum free light chain analyses benefit diagnosis of multiple myeloma in orthopedic patients with normal serum total proteins, creatinine, calcium, and hemoglobin"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3077-0893","authenticated-orcid":false,"given":"Zhongwei","family":"Jia","sequence":"first","affiliation":[{"name":"Clinical Laboratory Department, First Affiliated Hospital of Anhui Medical University , Hefei , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinxing","family":"Xia","sequence":"additional","affiliation":[{"name":"Clinical Laboratory Department, First Affiliated Hospital of Anhui Medical University , Hefei , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiong","family":"Lu","sequence":"additional","affiliation":[{"name":"Clinical Laboratory Department, First Affiliated Hospital of Anhui Medical University , Hefei , China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,12,23]]},"reference":[{"issue":"11","key":"2024070305534704400_CIT0001","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med."},{"issue":"2","key":"2024070305534704400_CIT0002","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/cancers13020217","article-title":"The role of tumor microenvironment in multiple myeloma development and progression","volume":"13","author":"Garc\u00eda-Ortiz","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2024070305534704400_CIT0003","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"issue":"4","key":"2024070305534704400_CIT0004","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/47.4.673","article-title":"Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine","volume":"47","author":"Bradwell","year":"2001","journal-title":"Clin Chem."},{"issue":"8","key":"2024070305534704400_CIT0005","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1515\/CCLM.2011.624","article-title":"N Latex FLC \u2013 new monoclonal high-performance assays for the determination of free light chain kappa and lambda","volume":"49","author":"Velthuis","year":"2011","journal-title":"Clin Chem Lab Med."},{"issue":"10272","key":"2024070305534704400_CIT0006","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet."},{"key":"2024070305534704400_CIT0007","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cca.2019.12.026","article-title":"Emerging biomarkers in multiple myeloma: a review","volume":"503","author":"Gupta","year":"2020","journal-title":"Clin Chim Acta"},{"issue":"3","key":"2024070305534704400_CIT0008","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2141.2004.05045.x","article-title":"Serum free light chains for monitoring multiple myeloma","volume":"126","author":"Mead","year":"2004","journal-title":"Br J Haematol."},{"issue":"1","key":"2024070305534704400_CIT0009","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41408-019-0267-8","article-title":"Comparison of three different serum-free light-chain assays\u2014implications on diagnostic and therapeutic monitoring of multiple myeloma","volume":"10","author":"Schieferdecker","year":"2020","journal-title":"Blood Cancer J."},{"issue":"2","key":"2024070305534704400_CIT0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00408-4","article-title":"Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report","volume":"11","author":"Murray","year":"2021","journal-title":"Blood Cancer J."},{"issue":"6","key":"2024070305534704400_CIT0011","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1515\/cclm-2015-0938","article-title":"Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis","volume":"54","author":"Mollee","year":"2016","journal-title":"Clin Chem Lab Med."},{"issue":"7","key":"2024070305534704400_CIT0012","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ajh.25819","article-title":"Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment","volume":"95","author":"Gertz","year":"2020","journal-title":"Am J Hematol."},{"issue":"23","key":"2024070305534704400_CIT0013","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.3390\/cancers13236017","article-title":"Role of serum free light chain assay in relapsed\/refractory multiple myeloma: a real-life unicentric retrospective study","volume":"13","author":"Markovic","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2024070305534704400_CIT0014","doi-asserted-by":"crossref","first-page":"46","DOI":"10.14740\/jocmr2802w","article-title":"Serum free light chain assay and \u03ba\/\u03bb ratio: performance in patients with monoclonal gammopathy-high false negative rate for \u03ba\/\u03bb ratio","volume":"9","author":"Singh","year":"2017","journal-title":"J Clin Med Res."},{"key":"2024070305534704400_CIT0015","doi-asserted-by":"crossref","first-page":"647238","DOI":"10.1155\/2014\/647238","article-title":"Clinical comparisons of two free light chain assays to immunofixation electrophoresis for detecting monoclonal gammopathy","volume":"2014","author":"Kim","year":"2014","journal-title":"Biomed Res Int."},{"issue":"18","key":"2024070305534704400_CIT0016","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2010-10-299529","article-title":"Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3","volume":"117","author":"Dimopoulos","year":"2011","journal-title":"Blood."},{"issue":"12","key":"2024070305534704400_CIT0017","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"issue":"3","key":"2024070305534704400_CIT0018","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/COC.0b013e3182a4676b","article-title":"Emerging therapies in multiple myeloma","volume":"38","author":"El-Amm","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"2024070305534704400_CIT0019","doi-asserted-by":"crossref","first-page":"m3176","DOI":"10.1136\/bmj.m3176","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Shah","year":"2020","journal-title":"BMJ"}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/55\/4\/454\/58391920\/lmad104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/55\/4\/454\/58391920\/lmad104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T05:57:59Z","timestamp":1719986279000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/55\/4\/454\/7492630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,23]]},"references-count":19,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,12,23]]},"published-print":{"date-parts":[[2024,7,3]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmad104","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"value":"0007-5027","type":"print"},{"value":"1943-7730","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2023,12,23]]}}}